Neutralization of a Clade B Primary Isolate by Sera from Human Immunodeficiency Virus—Uninfected Recipients of Candidate AIDS Vaccines | Zendy

Susan ZollaPazner | Zendy; Carl R. Alving | Zendy; Robert B. Belshe | Zendy; Phillip W. Berman | Zendy; Sherri Burda | Zendy; Padmasree Chigurupati | Zendy; M L Clements | Zendy; AnneMarie Duliège | Zendy; JeanLouis Excler | Zendy; Catarina E. Hioe | Zendy; James O. Kahn | Zendy; M. Juliana McElrath | Zendy; Sandra Sharpe | Zendy; Faruk Sinangil | Zendy; Kathelyn S. Steimer | Zendy; Mary Clare Walker | Zendy; Nabila M. Wassef | Zendy; Serena Xu | Zendy

Open Access

Neutralization of a Clade B Primary Isolate by Sera from Human Immunodeficiency Virus—Uninfected Recipients of Candidate AIDS Vaccines

Author(s) -

Susan ZollaPazner,

Carl R. Alving,

Robert B. Belshe,

Phillip W. Berman,

Sherri Burda,

Padmasree Chigurupati,

M L Clements,

AnneMarie Duliège,

JeanLouis Excler,

Catarina E. Hioe,

James O. Kahn,

M. Juliana McElrath,

Sandra Sharpe,

Faruk Sinangil,

Kathelyn S. Steimer,

Mary Clare Walker,

Nabila M. Wassef,

Serena Xu

Publication year - 1997

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/513969

Subject(s) - virology , neutralization , antibody , biology , neutralizing antibody , virus , hiv vaccine , immunology , vaccine trial , vaccination

The inability of antibodies induced by experimental human immunodeficiency virus type 1 (HIV-1) vaccines to neutralize HIV-1 primary isolates may be due to a failure to elicit such antibodies, antigenic differences between the vaccine and the strains tested, insensitivity of the assays used, or to a combination of factors. New neutralization assays were used to determine the ability of candidate AIDS vaccines to generate neutralizing antibodies for clade B primary isolate BZ167, which is closely related in portions of its envelope to the immunizing strains. Sera from HIV-uninfected volunteers in vaccine trials were tested, and neutralizing activity was found in recipients of recombinant (r) gp120MN or of rgp160MN-containing canarypox boosted with rgp120SF-2. Detection of antibodies that neutralize primary isolate BZ167 correlated with neutralizing activity for homologous vaccine strains. These data demonstrate that certain candidate AIDS vaccines can elicit antibodies that neutralize a primary isolate of HIV-1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research